OSCR
Oscar Health, Inc.
OSCR's fundamentals are strong: revenue grew 55% and its operating margin went from −1.9% to 5.4%. Its PE isn't a useful guide right now because of how its recent earnings were reported.
SNN
Smith & Nephew plc
There isn't enough reported data to score SNN yet.
OSCR Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Healthy | |
| Strong | |
| Strong |
OSCR's revenue, profitability, cash flow and balance sheet are all currently healthy.
SNN Fundamentals
| Metric | Status |
|---|---|
| Unavailable | |
| Unavailable | |
| Unavailable | |
| Unavailable |
There isn't enough reported data to rate SNN's fundamentals.
OSCR PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 12x | $31.94 | — |
| Current | 13x | $31.94 | — |
| Cheap | 21x | $52.73 | +65% |
| Fair | 35x | $87.23 | +173% |
| Expensive | 130x | $322 | +907% |
Historical ranges are pointers, not guarantees.
OSCR's PE is 13x, but its earnings don't support one, so it isn't a reliable read right now.
SNN PE Valuation
SNN has no meaningful PE right now: it lost money over the past year.
OSCR Forward outlook
| Metric | Outlook |
|---|---|
| Improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
Analysts expect strong earnings and revenue growth for OSCR, with profitability improving.
SNN Forward outlook
There aren't enough analyst estimates for SNN to show an outlook.
OSCR Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $2.61 | +5.6% |
| Q3 2026 | $2.47 | +$3.47 |
| Q2 2026 | $1.45 | +$2.14 |
| Q1 2026 | -$0.54 | -235% |
| Q4 2025 | -$1.69 | -1790% |
| Q3 2025 | -$1.00 | -$0.92 |
| Q2 2025 | -$0.69 | -$0.54 |
| Q1 2025 | $0.40 | +$0.82 |
| Q4 2024 | $0.10 | +$1.32 |
OSCR has returned to profit: it earned $2.47 per share over the past year, after losing money the year before.
SNN Earnings Per Share
SNN and OSCR do not have enough comparable growth data to identify a winner.
OSCR Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $5.1B | +72% |
| Q2 2026 | $4.9B | +70% |
| Q1 2026 | $4.6B | +53% |
| Q4 2025 | $2.8B | +17% |
| Q3 2025 | $3B | +23% |
| Q2 2025 | $2.9B | +29% |
| Q1 2025 | $3B | +42% |
| Q4 2024 | $2.4B | +67% |
OSCR has the edge over SNN in the latest year-over-year revenue comparison.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 3.5% | +7.8 points |
| Q2 2026 | 8% | +16 points |
| Q1 2026 | 15% | +5.4 points |
| Q4 2025 | -12% | -5.7 points |
| Q3 2025 | -4.3% | -2.3 points |
| Q2 2025 | -8.1% | -11 points |
| Q1 2025 | 9.8% | +1.1 points |
| Q4 2024 | -6.2% | +4 points |
OSCR's operating margin was 3.5% last quarter, up 7.8 points from the same quarter a year ago.
SNN Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q2 2026 | $3.1B | +4.6% |
| Q4 2025 | $3.2B | +7.4% |
| Q2 2025 | $3B | +4.7% |
| Q4 2024 | $3B | +6% |
| Q2 2024 | $2.8B | +3.4% |
| Q4 2023 | $2.8B | +7.6% |
| Q2 2023 | $2.7B | +5.2% |
| Q4 2022 | $2.6B | +0.1% |
SNN's revenue has grown year over year for nine quarters in a row: $3.1B last quarter, up 9.6% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2026 | 14% | +2.9 points |
| Q4 2025 | 11% | +6.1 points |
| Q2 2025 | 14% | +4.4 points |
| Q4 2024 | 11% | +3.1 points |
| Q2 2024 | 12% | +2.3 points |
| Q4 2023 | 5.3% | -8.2 points |
| Q2 2023 | 10% | +0.9 points |
| Q4 2022 | 8% | -3.9 points |
SNN has the edge over OSCR on profitability, with a higher operating margin.
OSCR Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$1.2B | -$238.2M |
| Q2 2026 | $2.1B | +316% |
| Q1 2026 | $2.6B | +200% |
| Q4 2025 | $662.8M | +95% |
| Q3 2025 | -$973.7M | -$466M |
| Q2 2025 | $499.8M | +2.1% |
| Q1 2025 | $869.5M | +38% |
| Q4 2024 | $340M | +17% |
OSCR usually generates cash, though not every quarter: the latest was −$1.2B, but it generated $4.1B over the past year.
SNN Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2026 | $260M | +1.2% |
| Q4 2025 | $595M | +10% |
| Q2 2025 | $257M | +289% |
| Q4 2024 | $540M | +130% |
| Q2 2024 | $66M | +$120M |
| Q4 2023 | $235M | +209% |
| Q2 2023 | -$54M | -259% |
| Q4 2022 | $76M | -73% |
SNN generated $1.7B in free cash flow over the past year, about five times what it generated the year before.
OSCR Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +3.9% | +13M shares |
| 1 year | +34% | +87.2M shares |
| 3 years | +55% | +123M shares |
| 5 years | +66% | +138M shares |
| Available history | +71% | +143M shares |
OSCR has 346M diluted shares, up 34% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2020 | — |
| Q3 2020 | — |
| Q2 2020 | — |
| Q1 2020 | — |
SNN Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -1.4% | -6.1M shares |
| 1 year | -1.5% | -6.3M shares |
| 3 years | -51% | -447M shares |
| 5 years | -52% | -466M shares |
| Available history | -52% | -470M shares |
SNN has the edge over OSCR on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q2 2026 | $116M |
| Q4 2025 | $502M |
| Q2 2025 | — |
| Q4 2024 | — |
| Q2 2024 | — |
| Q4 2023 | $1M |
| Q2 2023 | — |
| Q4 2022 | $25M |
OSCR Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -4.2x | Net Cash |
| Q2 2026 | -5.5x | Net Cash |
| Q1 2026 | -110.0x | Net Cash |
| Q1 2025 | -9.7x | Net Cash |
| Q4 2024 | -13.7x | Net Cash |
| Q3 2024 | -10.1x | Net Cash |
| Q2 2024 | -24.0x | Net Cash |
| Q1 2024 | -217.7x | Net Cash |
OSCR has more cash than debt.
SNN Net Leverage
SNN's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
OSCR Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 58.7 | Neutral |
| Stochastic | 44.9 | Neutral |
OSCR's weekly RSI is 59 (neutral) and its Stochastic is 45 (neutral).
SNN Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 55.1 | Neutral |
| Stochastic | 65.6 | Neutral |
SNN's weekly RSI is 55 (neutral) and its Stochastic is 66 (neutral).
OSCR PE vs Healthcare Sector
| Metric | OSCR | Sector median | Relative |
|---|---|---|---|
| PE | 13x | 26x | 50% below |
| PE % | 3 | 35 | 32 pts below |
OSCR has the edge over SNN on valuation relative to its sector.
SNN PE vs Healthcare Sector
| Metric | SNN | Sector median | Relative |
|---|---|---|---|
| PE | 19x | 26x | 26% below |
| PE % | 24 | 29 | 5 pts below |
SNN has no meaningful PE right now: it lost money over the past year.
OSCR Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $31.2 | 2.3% above |
| 20 week MA | $31.1 | 2.8% above |
| 50 week MA | $22.9 | 39% above |
| 100 week MA | $19.3 | 65% above |
| 200 week MA | $15.5 | 106% above |
OSCR has the edge over SNN on trend strength, trading above more of its moving averages.
SNN Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $29.0 | 6.7% above |
| 20 week MA | $29.4 | 5.4% above |
| 50 week MA | $31.3 | 1% below |
| 100 week MA | $30.9 | 0.4% above |
| 200 week MA | $29.3 | 5.9% above |
SNN's trend is mixed: it's above four of its five weekly moving averages, and 5.9% above its 200-week average.
OSCR Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2021 | $31.0 | $8.02 | -74% |
| 2022 | $8.02 | $2.21 | -72% |
| 2023 | $2.21 | $9.15 | +314% |
| 2024 | $9.15 | $13.8 | +51% |
| 2025 | $13.8 | $14.9 | +8% |
| 2026 YTD | $14.9 | $31.9 | +114% |
OSCR has the edge over SNN on returns for 2026, with the stronger performance.
SNN Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $48.5 | $42.1 | -13% |
| 2021 | $42.1 | $34.0 | -19% |
| 2022 | $34.0 | $26.9 | -21% |
| 2023 | $26.9 | $27.3 | +1.5% |
| 2024 | $27.3 | $24.8 | -9.1% |
| 2025 | $24.8 | $33.0 | +33% |
| 2026 YTD | $33.0 | $31.0 | -6.2% |
SNN has finished lower in four of the last six years. It's down 6.2% so far in 2026.